/EXDI

EXDI Stock - Exactus, Inc.

Q: What is the analyst price target for EXDI?

Analyst price target information is not currently available for EXDI.

Q: What is EXDI's market cap?

Market capitalization information is not currently available for EXDI.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$0.07-10.96%

$0.01 (-10.96%) • Apr 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.07

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EXDI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2016

FY2017

FY2018

FY2019

FY2020

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta4.32

52W High$3.33

52W Low$0.04

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	$2.72M	$345,680	N/A	N/A	N/A
Gross Profit	$-2,720,000	$-1,700,000	N/A	N/A	N/A
Gross Margin	-100.0%	-491.8%	N/A	N/A	N/A
Operating Income	$-10,555,000	$-10,878,000	$-2,436,000	$-2,075,000	$-1,597,000
Net Income	$-10,941,000	$-9,687,000	$-4,337,000	$-3,861,000	$-1,603,000
Net Margin	-402.2%	-2802.3%	N/A	N/A	N/A
EPS	$-0.22	$-0.29	$-0.91	$-0.91	$-0.67

Company Overview

Exactus, Inc. produces and supplies hemp-derived ingredients and feminized hemp genetics. It provides cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products to the cosmetic, wellness, food, beverage, pharmaceutical, and pet industries. The company's specialty ingredients include CBD, CBG, CBN, and CBC isolates; CBD and CBG distillates; CBD water-soluble; CBD and CBG biomass; CBD AND CBG flowers; and CBD crude oil. It also provides a range of custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, supplements, and other products. The company is based in Delray Beach, Florida. Exactus, Inc. is a subsidiary of Ceed2Med, LLC.

Visit Website

Frequently Asked Questions about EXDI

What is EXDI's current stock price?

Exactus, Inc. (EXDI) is currently trading at $0.07 per share. The stock has moved -10.96% today.

What is the analyst price target for EXDI?

No analyst price targets are currently available for this stock.

What sector is Exactus, Inc. in?

Exactus, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is EXDI's market cap?

Exactus, Inc. has a market capitalization of N/A, making it a small-cap company.

Does EXDI pay dividends?

No, Exactus, Inc. does not currently pay a dividend to shareholders.